Under the strategic alliance, both the companies will offer contract development and manufacturing of ADCs by simplifying the supply chain and vendor management relationships.
Fujifilm Diosynth Biotechnologies commercial vice president Stephen Taylor said the strategic alliance with Piramal is a significant step in bringing a high-technology offering to the market place.
"Our customers will benefit from high quality, consistent material, rapid service and shorter logistical chains, saving time on the critical path of drug development," Taylor added.
The deal covers more than 150 biopharmaceuticals and over 300 batches of ADCs across 30 different NCEs.
Piramal formulations services president Aidan Walker said the deal allows the company to combine with Fujifilm Diosynth Biotechnologies to offer a service to customers for the production of antibody conjugates.
"Fujifilm Diosynth Biotechnologies has a long track-record in delivering successful biologics programmes, and this alliance will combine strengths from both companies for the benefit of our customers, and ultimately patients," Walker added.